参考文献/References:
［1］ 国家卫生计生委合理用药专家委员会.乳腺癌合理用药指南［M］.北京：人民卫生出版社,2019：3.
［2］ FERLAY J,COLOMBET M,SOERJOMATARAM I,et al．Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods［J］.Int J Cancer,2019,144(8):1941-1953.
［3］ EIERMANN W,PIENKOWSKI T,CROWN J,et al.Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal,node-positive breast cancer:BCIRG-005 trial［J］.J Clin Oncol,2011,29(29):3877-3884.
［4］ VRIENS B,VRIENS I,AARTS M,et al.Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer［J］.Breast Cancer Res Treat,2017,165(3):593-600.
［5］ SPARANO J.Defining a role and predicting benefit from platinum-based therapy in breast cancer:an evolving story［J］.J Clin Oncol,2015,33(1):1-3.
［6］ 杨晓晨,胡震,吴炅,等.中国汉族人群中BRCA1和BRCA2基因突变携带者患乳腺癌风险的研究［J］.中国癌症杂志,2015,25(4):247-252.
［7］ NAROD S.BRCA mutations in the management of breast cancer:the state of the art［J］.Nat Rev Clin Oncol,2010,7(12):702-707.
［8］ BYRSKI T,GRONWALD J,HUZARSKI T,et al.Pathologic complete response rates in young women with BRCA1- positive breast cancers after neoadjuvant chemotherapy［J］.J Clin Oncol,2010,28(3):375-379.
［9］ CORTAZAR P,ZHANG L,UNTCH M,et al.Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis［J］.Lancet,2014,384 (9938):164-172.
［10］ POGGIO F,BRUZZONE M,CEPPI M,et al.Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer:a systematic review and meta-analysis［J］.Ann Oncol,2018,29(7):1497-1508.
［11］ MASUDA N,LEE S,OHTANI S,et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy［J］.N Engl J Med,2017,376(22):2147-2159.
［12］ 中国乳腺癌新辅助治疗专家组.中国乳腺癌新辅助治疗专家共识（2019年版）［J］.中国癌症杂志,2019,29（5）:390-400.
［13］ KARAGIANNIS G,PASTORIZA J,WANG Y,et al.Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism ［J］.Sci Transl Med,2017,9(397):eaan0026.
［14］ KEKLIKOGLOU I,CIANCIARUSO C,GUC E,et al.Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models［J］.Nat Cell Biol,2019,21(2):190-202.
［15］ GIANNI L,EIERMANN W,SEMIGLAZOV V,et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer (the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort［J］.Lancet,2010,375(9712):377-384.
［16］ GIANNI L,PIENKOWSKI T,IM Y,et al.5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced,inflammatory,or early-stage HER2-positive breast cancer (NeoSphere):a multicentre,open-label,phase 2 randomised trial［J］.Lancet Oncol,2016,17(6):791-800.
［17］ SHAO Z,PANG D,YANG H,et al.Pertuzumab,trastuzumab,and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting:efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)［J］.Cancer Res，2019，79(4 Suppl):6-17.
［18］ GIANNI L,PIENKOWSKI T,IM Y,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer (NeoSphere):a randomised multicentre,open-label,phase 2 trial［J］.Lancet Oncol,2012,13(1):25-32.
［19］ SLAMON D,EIERMANN W,ROBERT N,et al.Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC-T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel,carboplatin and trastuzumab (TCH) in HER2+early breast cancer［J］.Cancer Res，2016，76(Suppl 4）:S5-04-S5-04.
［20］ 佟仲生.美国临床肿瘤学会HER2阳性进展期乳腺癌系统治疗临床实践指南( 2018) 更新解读［J］.临床外科杂志，2019,27（1）:17-20.
［21］ LLOMBART-CUSSAC A,CORTES J,PARE L,et al.HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA):an open-label,single-group,multicentre,phase 2 trial［J］.Lancet Oncol，2017,18(4)：545-554.
［22］ BASELGA J,BRADBURY I,EIDTMANN H,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):a randomised,open-label,multicentre,phase 3 trial［J］.Lancet，2012,379(9816)：633-640.
［23］ DE AZAMBUJA E,HOLMES A,PICCART-GEBHART M,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):survival outcomes of a randomised,open-label,multicentre,phase 3 trial and their association with pathological complete response［J］.Lancet Oncol，2014,15(10)：1137-1146.
［24］ BARROSO-SOUSA R,FONSECA REIS SILVA D,MACHADO ALESSI J V,et al．Neoadjuvant endocrine therapy in breast cancer：current role and future perspectives［J］．Ecancermedicalscience，2016，10：609．
［25］ SEMIGLAZOV V,SEMIGLAZOV V,DASHYAN G,et al．Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer ［J］．Cancer，2007，110(2) ：244-254．
［26］ ELLIS M,MA C.Letrozole in the neoadjuvant setting:the P024 trial［J］.Breast Cancer Res Treatment,2007,105 (Suppl 1):33-43.
［27］ ELLIS M,SUMAN V,HOOG J,et al．Randomized phase II neoadjuvant comparison between letrozole,anastrozole,and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer:Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031［J］．J Clin Oncol，2011，29(17)：2342-2349.
［28］ ELLIS M.Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer［J］.Breast (Edinburgh,Scotland),2017,34:104-107.
［29］ UNTCH M,HARBECK N,HUOBER J,et al.Primary therapy of patients with early breast cancer:evidence,controversies,consensus:opinions of german specialists to the 14th St.Gallen international breast cancer conference 2015 (Vienna 2015)［J］.Geburtshilfe Frauenheilkd，2015,75(6):556-565.
［30］ ELLIS M,SUMAN V,HOOG J,et al.Ki-67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer：results from the American College of Surgeons Oncology Group Z1031 Trial （Alliance）［J］.J Clin Oncol，2017，35（10）:1061-1069.
［31］ 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）乳腺癌诊疗指南（2019.V1）［M］.北京:人民卫生出版社,2019:49.
［32］ HENDERSON I,BERRY D,DEMETRI G,et al.Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer［J］.J Clin Oncol，2003，21(6):976-983.
［33］ SAMUEL J，WILSON J,BANDOS H,et al.N-ABP B—36：a randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU),epirubicin,and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer ［C］.Cancer Res,2015,75(9).Abstract nr S3-02.
［34］ 王铁军,耿慧,祝永刚,等.乳腺癌化疗现状及相关研究进展［J］.现代生物医学进展,2013,13（22）:4398-4400.
［35］ PAN H,PH D,GRY R,et al.20-year risks of breast-cancer recu-rrence after stopping endocrine therapy at 5 years［J］.N Engl J Med,2017,377(19):1836-1846.
［36］ LEMIEUX J,GOSS P,PARULEKAR W.Patient-reported outcomes from MA.17R:arandomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in post-menopausal women with early-stage breast cancer［J］.J Clin Oncol,2016,34(Suppl):abstrLBA506
［37］ HELLEMOND I,GEURTS S,TJAN-HEIJNEN V C G.Current Status of extended adjuvant endocrine therapy in early stage breast cancer［J］.Curr Treat Options Oncol,2018,19(5):26.
［38］ BLOK E J,KROEP J R,MEERSHOEK-KLEIN KRANENBARG E,et al.Optimal duration of extended adjuvant endocrine therapy for early breast cancerresults of the IDEAL trial (BOOG 2006-05)［J］.JNCI，2018，110(1)：1-48.
［39］ GNANT M,STEGER G,GREIL R,et al.A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy：results from 3 484 postmenopausal women in the ABCSG-16 trial［J］.Cancer Res，2018,78(Suppl 4)：S267-296.
［40］ 江泽飞,邵志敏,徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识 2016［J］.中华医学杂志,2016,96(14):1091-1096.
［41］ CURIGLIANO G,BURSTEIN H,WINER E,et al.De-escalating and escalating treatments for early-stage breast cancer:the St.Gallen international expert consensus conference on the primary therapy of early breast cancer 2017［J］.Ann Oncol,2017,28(8):1700-1712.
［42］ CAMERON D,PICCART-GEBHART M,GELBER R,et al.11 years′ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer:final analysis of the HERceptin Adjuvant (HERA) trial［J］.Lancet,2017,389(10075):1195-1205.
［43］ VON-MINCKWITZ G,PROCTER M,AZAMBUJA E D,et al.Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer［J］.N Engl J Med,2017,377(2):122-131.
［44］ CHAN A,DELALOGE S,HOLMES F,et al．Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer(ExteNET)：a muhicentre，randomised，doubleblind,placebo—controlled，phase 3 trial［J］．Lancet Oncol,2016,17(3)：367-377．
［45］ MIGUEL M,HOLMES F,EJLERTSEN B,et al．Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET)：5-year analysis of a randomised，double-blind,placebo-controlled,phase 3 trial［J］．Lancet Oncol,2017,18(12)：1688-1700．
［46］ SLAMON D,EIERMANN W,ROBERT N,et al．Adjuvant trastuzumab in HER2-positive breast cancer［J］．N Engl J Med,2011,365 (14)：1273-1283．
［47］ SLAMON D,EIERMANN W,ROBERT N,et al.Abstract S5-04:ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→H) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel，carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer［J］．Cancer Res,2016,76(4 Suppl):S5-04-S5-04.
［48］ 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2017年版）［J］.中国癌症杂志,2017,27(9):695-759.
［49］ 师金,梁迪,李道娟,等.全球女性乳腺癌流行情况研究［J］.中国肿瘤,2017,26(9):683-690.
［50］ 师弘，刘娟，王伟.乳腺癌新辅助化疗后降期患者改良根治术后放射治疗的疗效［J］.实用临床医药杂志，2019,23（2）:72-75.
［51］ 刘卫芳.对接受保乳手术的早期单发乳腺癌患者进行术后大分割放疗的效果［J］.当代医药论丛,2019,17(9):107-108.
［52］ FERRERO J M,HARDY-BESSARD A C,CAPITAIN O,et al.Weekly paclitaxel,capecitabine,and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative,metastatic,or locally advanced breast cancer:Results from the GINECO A-TaXel phase 2 study［J］.Cancer,2016,122:3119-3126.
［53］ HU X C,ZHANG J,XU B H,et al.Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple negative breast cancer (CBCSG006):a randomised,openlabel multicentre,phase 3 trial［J］.Lancet Oncol,2015,16(4):436-446.
［54］ UNTCH M,JACKISCH C,SCHNEEWEISS A,et al.Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto GBG 69):a randomised,phase 3 trial［J］.Lancet Oncol,2016,17(3):345-356.
［55］ VON MINCKWITZ G,SCHNEEWEISS A,LOIBL S,et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer(GeparSixtoGBG 66):a randomized phase 2 trial［J］.Lancet Oncol,2014,15(7):747-756.
［56］ SIKOV W M,BERRY D A,PEROU C M,et al.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III tri-ple-negative breast cancer:CALGB 40603(Alliance)［J］.J Clin Oncol,2015,33(1):13-21.
［57］ 袁芃.2016年美国临床肿瘤学会年会报道：三阴性乳腺癌研究新进展［J/CD］.中华乳腺病杂志（电子版）,2016,10（5）:264-268.DOI:10.3877/cma.j.issn.1674-0807.2016.05.003
［58］ ABDULKARIM B,CUARTERO J,HANSON J．Increased risk of locoregional recurrence for women with T1-T2N0 triple-negative breast cancer treated with modified radical mastectomy without adju vant radiation therapy compared with breast conserving therapy［J］.J Clin Oncol,2011,29(21):2852-2858.
［59］ ASANO Y,KASHIWAGI S,GOTO W,et al.Expression and clinical significance of androgen receptor in triple-negative breast cancer［J］.Cancers(Basel),2017,9(1):4.
［60］ MCGHAN L,MCCULLOUGH A,PROTHEROE C,et al.Androgen receptor-positive triple negative breast cancer：a unique breast cancer subtype［J］.Ann Surg Oncol，2014，21(2)：361-367.
［61］ QI J,YANG Y,ZHU H,et al.Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients［J］.Breast Cancer (Auckl),2012,6:1-8.
［62］ 陈俊青，陈占红，王晓稼．三阴性乳腺癌雄激素受体靶向治疗的研究进展［J］.肿瘤学杂志,2018,24(5):499-503.
［63］ TRAINA T A,MILLER K,YARDLEY D A,et al.Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer［J］.J Clin Oncol,2018,36(9):884-890.
［64］ BASELGA J,GOMEZ P,GREIL R,et al.Randomized phase lI study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients withmetastatic triple-negative breast cancer［J］.J Clin Oncol,2013,31(20):2586-2592.
［65］ 孙莉，赵毅.三阴性乳腺癌治疗的研究进展［J］．现代肿瘤医学，2019，27(13)：2420-2424.
［66］ NANDA R,CHOW L Q,DEES E C,et al.Pembrolizumab in patients with advanced triple-negative breast cancer:phase Ib KEYNOTE-012 study［J］.J Clin Oncol,2016,34(21):2460-2467.
［67］ ADAMS S,SCHMID P,RUGO H S,et al.Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer:cohort A of the phase II KEYNOTE-086 study［J］.Ann Oncol，2019，30(3):397-404.
［68］ 谈震东,杨文杰.槐耳颗粒在三阴性乳腺癌根治术后化疗中辅助治疗的临床效果［J］.实用癌症杂志,2017,32（l1）:1893-1895.
［69］ 王云生,张清媛.三阴型乳腺癌靶向治疗研究进展［J］.新乡医学院学报,2016,33（9）:815-818.